Compare Oatly Group AB - ADR (OTLY) vs Pfizer Inc (PFE) Price & Performance

OTLY trades at $10.37, down 1.33% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. Fundamentally, the company shows improving revenue growth ($862M in 2025, projected $925M in 2026) and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.

The outlook suggests cautious optimism as Oatly demonstrates operational improvements and revenue acceleration, but significant risks remain including persistent negative cash flow, high debt levels, and competitive pressures in the plant-based beverage market. The stock offers potential for recovery if the company can achieve its projected path toward profitability.

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.